Agile Therapeutics, Inc. (NASDAQ:AGRX)‘s stock had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott in a report issued on Friday. They currently have a $15.00 price target on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target suggests a potential upside of 179.33% from the stock’s previous close.

AGRX has been the topic of several other research reports. ValuEngine downgraded shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, June 14th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price objective on shares of Agile Therapeutics in a report on Monday, May 8th. HC Wainwright started coverage on shares of Agile Therapeutics in a report on Wednesday. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Royal Bank Of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a report on Sunday, July 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.93.

Shares of Agile Therapeutics (AGRX) traded down 3.259% during mid-day trading on Friday, hitting $5.195. 62,229 shares of the stock were exchanged. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.15. The stock has a 50-day moving average price of $3.90 and a 200 day moving average price of $3.09. The firm’s market cap is $149.65 million.

WARNING: “Agile Therapeutics, Inc. (AGRX) Earns Buy Rating from Janney Montgomery Scott” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/21/agile-therapeutics-inc-agrx-earns-buy-rating-from-janney-montgomery-scott-2.html.

In other Agile Therapeutics news, Chairman Alfred Altomari purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The shares were bought at an average price of $3.51 per share, for a total transaction of $35,100.00. Following the acquisition, the chairman now owns 151,587 shares in the company, valued at $532,070.37. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Renee Selman purchased 53,333 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The stock was acquired at an average price of $3.68 per share, for a total transaction of $196,265.44. Following the acquisition, the insider now owns 53,333 shares in the company, valued at approximately $196,265.44. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by corporate insiders.

An institutional investor recently raised its position in Agile Therapeutics stock. Renaissance Technologies LLC raised its stake in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 209.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,000 shares of the specialty pharmaceutical company’s stock after buying an additional 43,300 shares during the period. Renaissance Technologies LLC owned approximately 0.22% of Agile Therapeutics worth $365,000 as of its most recent filing with the SEC. 79.78% of the stock is currently owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.